Semaglutide vs Tirzepatide

Semaglutide and tirzepatide are the two most prescribed weight loss medications in the world. Both belong to the incretin class, both are given as weekly injections, and both produce weight loss that was unthinkable from pharmacotherapy a decade ago. But they are not the same drug. They differ in mechanism, magnitude of weight loss, cardiovascular evidence, available formulations, and cost. This guide breaks down every meaningful difference using data from the STEP, SURMOUNT, SELECT, and SURPASS clinical trial programs.

Both medications require a prescription. This comparison is intended to inform discussions with a qualified physician, not to replace medical advice.

How They Work Differently

Both semaglutide and tirzepatide reduce appetite, slow gastric emptying, and improve insulin sensitivity. Where they diverge is at the receptor level.

Semaglutide is a pure GLP-1 receptor agonist. It mimics the natural incretin hormone GLP-1, which is released from the gut after eating. GLP-1 receptor activation in the brain suppresses appetite, in the stomach slows gastric motility, and in the pancreas enhances glucose-dependent insulin secretion. The result is reduced food intake, improved glycemic control, and progressive weight loss.

Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is the other major incretin hormone released after eating. The GIP receptor is expressed in adipose tissue, the brain, and the pancreas. Preclinical data suggest GIP receptor activation enhances fat oxidation, improves lipid metabolism, and may contribute to appetite suppression through pathways distinct from GLP-1 alone. The dual mechanism appears to produce additive or synergistic effects on weight loss beyond what GLP-1 activation achieves independently.

This mechanistic difference is the most likely explanation for tirzepatide's greater weight loss efficacy in clinical trials. It also raises the question of whether the GI tolerability profile differs, a point addressed in the side effects section below.

Weight Loss Efficacy

The clinical trial data for both drugs is extensive. The most relevant comparisons come from the STEP program (semaglutide), the SURMOUNT program (tirzepatide), and the head-to-head SURMOUNT-5 trial.

Semaglutide: STEP Trials

The STEP program evaluated semaglutide 2.4 mg weekly across multiple populations. STEP 1 enrolled 1,961 adults with obesity or overweight with comorbidities and demonstrated 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. In STEP 1, 86% of semaglutide-treated participants achieved at least 5% weight loss, and one-third lost 20% or more. STEP 5 confirmed durability at 2 years: mean weight loss was 15.2% at week 104.

In January 2025, the STEP UP trial reported results for a higher 7.2 mg dose, achieving 20.7% mean weight loss at 72 weeks, substantially closing the gap with tirzepatide. This dose is not yet widely available but signals that semaglutide's ceiling has not been reached.

Tirzepatide: SURMOUNT Trials

The SURMOUNT program evaluated tirzepatide at 5 mg, 10 mg, and 15 mg weekly. SURMOUNT-1 enrolled 2,539 adults without diabetes and reported dose-dependent results at 72 weeks using the treatment-policy estimand: 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) mean weight loss. On the efficacy estimand (participants who adhered to treatment), results were higher: 16.0%, 21.4%, and 22.5%, respectively. At the 15 mg dose, 63% of participants achieved at least 20% weight reduction, and 36% achieved at least 25%.

Head-to-Head: SURMOUNT-5

The SURMOUNT-5 trial is the definitive direct comparison. This open-label, 72-week trial randomized 751 adults with obesity to maximum tolerated doses of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg). Tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide, a difference of 6.5 percentage points. In absolute terms, tirzepatide users lost a mean of 22.8 kg (50.3 lb) compared to 15.0 kg (33.1 lb) for semaglutide. Nearly one-third of tirzepatide participants (31.6%) achieved at least 25% weight loss, compared to 16.1% on semaglutide.

The trial has limitations. It was open-label (participants knew which drug they received), and it compared standard maximum doses, not the higher 7.2 mg semaglutide dose from STEP UP, which was not yet available. A blinded trial comparing optimized doses of both drugs would provide a more definitive answer.

Cardiovascular Benefits

Cardiovascular outcomes data is a critical differentiator between these two medications in 2026.

Semaglutide: SELECT Trial

The SELECT trial is the landmark study. It enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or higher, without diabetes. Over a mean follow-up of 39.8 months, semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% compared to placebo (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001). This made semaglutide the first obesity medication to demonstrate a direct reduction in major adverse cardiovascular events.

Tirzepatide: SURPASS-CVOT

The SURPASS-CVOT trial compared tirzepatide to dulaglutide (another GLP-1 agonist) in patients with type 2 diabetes and atherosclerotic cardiovascular disease over a median of 4 years. Tirzepatide met the primary endpoint of cardiovascular noninferiority to dulaglutide (HR 0.92; 95% CI, 0.83 to 1.01). The result was statistically noninferior but did not reach superiority. Notably, all-cause mortality was 16% lower with tirzepatide than dulaglutide (HR 0.84; 95% CI, 0.75 to 0.94), and an expanded MACE endpoint including coronary revascularization reached statistical significance.

Importantly, SURPASS-CVOT compared tirzepatide to an active comparator (dulaglutide), not placebo. Demonstrating superiority over another drug that itself reduces cardiovascular events is a higher bar than demonstrating superiority over placebo. The results suggest tirzepatide has cardiovascular benefit, but the evidence is less definitive than semaglutide's placebo-controlled SELECT data. A dedicated placebo-controlled cardiovascular outcomes trial for tirzepatide in obesity has not been completed.

Side Effect Comparison

Both medications share a similar gastrointestinal side effect profile, consistent with the GLP-1 receptor agonist class. The most common adverse events are nausea, diarrhea, vomiting, and constipation, occurring primarily during dose escalation and typically resolving with continued use.

Semaglutide (STEP 1 to 3 Pooled Data)

With semaglutide 2.4 mg, nausea occurred in 43.9% of participants (vs 16.1% placebo), diarrhea in 29.7% (vs 15.9%), vomiting in 24.5% (vs 6.3%), and constipation in 24.2% (vs 10.0%).

Tirzepatide (SURMOUNT-1 Data)

Across tirzepatide doses in SURMOUNT-1, nausea occurred in 24.6% (5 mg), 33.3% (10 mg), and 31.0% (15 mg) of participants, compared to 9.5% with placebo. Diarrhea occurred in 18.7%, 21.2%, and 23.0% respectively (vs 7.3% placebo). Vomiting occurred in 8.3%, 10.7%, and 12.2% (vs 1.7% placebo). Constipation occurred in 16.8%, 17.1%, and 11.7% (vs 5.8% placebo).

Cross-trial comparisons should be interpreted cautiously because the STEP and SURMOUNT programs enrolled different populations with different designs. However, the SURMOUNT-5 head-to-head trial reported that gastrointestinal adverse events occurred at broadly comparable rates between tirzepatide and semaglutide, with most classified as mild to moderate. Both drugs carried similar discontinuation rates due to adverse events.

Most GI events in both programs were nonserious (over 99%) and mild to moderate in severity (over 98%). Severe gastrointestinal adverse events occurred in approximately 4% of semaglutide-treated participants in the pooled STEP analysis. Both medications carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Cost and Insurance Coverage

Cost remains one of the most significant barriers to both medications.

List Prices

Wegovy injectable carries a list price of approximately $1,349 per month. Zepbound lists at approximately $1,060 to $1,200 per month depending on dose.

Manufacturer Savings Programs

Both manufacturers have introduced aggressive cash-pay options. Novo Nordisk offers the oral Wegovy pill at $149 to $299 per month through NovoCare Pharmacy depending on dose. Injectable Wegovy is available at $199 per month for the lower titration doses through the same program. Eli Lilly offers Zepbound single-dose vials at $299 to $449 per month through LillyDirect, depending on dose.

Insurance Coverage

With commercial insurance that covers weight loss medications, both manufacturers offer copay savings cards that can reduce out-of-pocket costs to as little as $25 per month. However, coverage is not universal. Many employer-sponsored plans and most Medicare and Medicaid plans exclude weight loss medications from their formularies. The proportion of large employers covering GLP-1 medications for obesity is growing (estimated at over 25% in 2026, up from approximately 20% in 2025) but gaps remain substantial.

Coverage is more likely when these medications are prescribed for type 2 diabetes (as Ozempic or Mounjaro) rather than weight management (as Wegovy or Zepbound). Patients should verify formulary inclusion and prior authorization requirements with their specific plan before starting therapy.

Who Should Choose Semaglutide

Semaglutide may be the better choice in several clinical scenarios.

Patients with established cardiovascular disease benefit from semaglutide's proven 20% MACE reduction in the SELECT trial. No other obesity medication has demonstrated this level of cardiovascular protection in a placebo-controlled trial.

Patients who prefer or need an oral formulation can now use the Wegovy tablet, which eliminates the need for weekly injections while achieving comparable weight loss.

Patients who have responded well to semaglutide already should consider whether switching is justified. Switching from a drug that is working well introduces a new titration period and potential for different side effects.

Patients with limited insurance coverage may find semaglutide easier to access, particularly through the oral formulation's lower cash-pay pricing ($149 to $299 per month).

Patients and clinicians who prioritize long-term safety data can draw on a larger and longer body of evidence with semaglutide. Wegovy was approved 2.5 years before Zepbound, and the STEP and SELECT trial programs together represent over 30,000 participants with follow-up extending beyond 3 years.

Who Should Choose Tirzepatide

Tirzepatide may be the better choice in other clinical scenarios.

Patients whose primary goal is maximum weight loss are likely to achieve greater results with tirzepatide. The SURMOUNT-5 head-to-head trial demonstrated a consistent and clinically meaningful 6.5 percentage point advantage over semaglutide.

Patients who have plateaued on semaglutide may benefit from switching to tirzepatide's dual-receptor mechanism. The addition of GIP receptor activation targets different physiologic pathways and can produce further weight loss in patients who have stopped responding to GLP-1 monotherapy.

Patients with type 2 diabetes seeking optimal glycemic control may benefit from tirzepatide's generally greater A1C reductions, as shown in the SURPASS-2 trial where tirzepatide outperformed semaglutide 1 mg at all doses tested.

Patients who experienced intolerable nausea on semaglutide sometimes find tirzepatide better tolerated, likely due to the GIP component's effects on gastric motility. This varies by individual and is not guaranteed, but physician-supervised switching is a reasonable strategy when GI side effects limit semaglutide use.

Can You Switch Between Them?

Yes. Switching between semaglutide and tirzepatide is done routinely under physician supervision. There are key practical considerations.

When switching from semaglutide to tirzepatide, tirzepatide should be started at the lowest dose (2.5 mg weekly) regardless of the patient's previous semaglutide dose. This is because tirzepatide's dual-receptor mechanism can produce different gastrointestinal effects, and starting low reduces the risk of adverse events. Most providers recommend initiating tirzepatide approximately one week after the last semaglutide injection, aligning with the patient's regular injection schedule. Standard titration then proceeds with dose increases every 4 weeks.

When switching from tirzepatide to semaglutide, the same principle applies: start at 0.25 mg weekly and titrate upward per the standard Wegovy schedule. This is particularly relevant for patients who experience insurance changes or want to transition to the oral formulation.

Expect a re-titration period. Regardless of direction, switching means returning to a starting dose and spending several weeks to months titrating back to a therapeutic dose. Some patients experience temporary weight regain during this transition. Physician oversight is important to manage expectations and optimize timing.

Common reasons for switching include inadequate weight loss response, intolerable side effects, insurance formulary changes, cost considerations, and preference for an oral formulation (currently available only with semaglutide).

Conclusion

Tirzepatide produces greater average weight loss than semaglutide at currently approved standard maximum doses. The SURMOUNT-5 head-to-head trial leaves little ambiguity on this point: 20.2% versus 13.7% over 72 weeks. For patients whose primary goal is maximum weight reduction, tirzepatide is the stronger option on current evidence.

Semaglutide brings advantages that matter for specific populations. The SELECT trial provides level-one evidence for cardiovascular risk reduction that no other obesity medication can match. The oral formulation expands accessibility and eliminates injection burden. A longer track record in clinical practice and published literature provides additional reassurance for patients and prescribers.

Neither drug is universally superior. The choice between semaglutide and tirzepatide depends on individual goals, medical history, cardiovascular risk, tolerability, insurance coverage, and formulation preference. Both represent transformative advances in obesity pharmacotherapy, and both are best used as part of a comprehensive treatment plan that includes dietary modification, physical activity, and ongoing medical monitoring.